Alpha-1 Advocacy Alliance - Alpha-1 Lung Disease

Won't you sign up for membership? Simply click HERE
Joining is free, easy and private.

to sign up and become a member of our growing community of committed individuals striving to be well informed and educated about Alpha 1.

Read our Privacy Policy and be assured we are here to help. Let us know what we can do for YOU!

Testing for AAT Deficiency
Simply click HERE Alpha One International Registry
provides AAT Deficiency Testing. This AAT Deficiency Testing is a
COMPLETE CONFIDENCIAL TESTING SERVICE
and WITHOUT COST TO YOU.
This testing will include measuring the CONCENTRATION of AAT in your blood, determining the TYPE of ATT in your blood and (where appropriate) determining your AAT genotype by testing the DNA in your blood; State of the art, full-spectrum Alpha-1 Testing .

Please read the detail at: AAT Deficiency Detection Center

Researchers identify genes associated
with lung transplant rejection

(2005-07-17)

Researchers at the San Francisco VA Medical Center (SFVAMC) and the University of California, San Francisco (UCSF) have identified six genes associated with lymphocytic bronchitis, which is thought to lead to obliterative bronchitis (OB), the most common cause of long-term failure of transplanted lungs.

The researchers hope their results will lead to an earlier, more sensitive, and more accurate standard test for chronic lung rejection, as well as greater understanding of the rejection process.

The study is being published in the September 2005 issue of the Journal of Heart and Lung Transplantation, currently available online.

In obliterative bronchitis, scar tissue forms in breathing passages of the transplanted lung, narrowing them and eventually making it impossible for the recipient to breathe. The exact cause is unknown, but it is believed to be related to rejection of the lung by the recipient's body.

"For lung transplant patients, the biggest barrier to long-term survival is control of rejection," says principal investigator George Caughey, MD, head of Pulmonary and Critical Care Medicine at SFVAMC. "If we know rejection is occurring, we can adjust the patient's medication to try and prevent it. But the problem with lung transplants is that it's hard to detect chronic rejection." Currently, he says, OB is best detected through a breathing test--but by the time the disease has a perceptible impact on the patient's ability to breathe, it's often too late to treat effectively.

Caughey and his fellow researchers studied lung biopsy samples from 22 lung transplant patients, with the goal of detecting genes and gene products associated with inflammation and formation of scar tissue in breathing passages. Using a customized version of a conventional laboratory technique, they found that they were able to look at hundreds of gene products simultaneously in lung tissue samples only a few millimeters across. "That was our first achievement: being able to accurately measure that many genes in small samples," notes Caughey, who is also a professor of medicine at UCSF. "We succeeded way beyond our expectations."

The researchers then correlated the genetic test results with results from microscopic pathology examinations, tissue cultures, X-rays, CT scans, and breathing tests in each patient. They identified six genes that correlate with lymphocytic bronchitis, potentially opening the way to a genetic test that would identify OB before it manifests. "The beauty of this approach is that it could be applied in a regular laboratory," Caughey says.

However, he cautions, "we need to validate this data in a larger, separate set of patients to prove that these biomarker genes actually work. And we're testing that now." Currently, Caughey's research team is studying biopsy samples from more than 100 UCSF lung transplant patients, who regularly undergo biopsies as part of standard follow-up care.

Another potential benefit of the research, predicts Caughey, will be a better understanding of lung rejection at the genetic level. In turn, he believes, this could lead to the development of medications that directly target genes responsible for the scarring process in the lung, instead of anti-rejection drugs that broadly compromise the immune system, which are the major tools currently available to fight lung rejection.

Co-authors of the study were Xiang Xu, MD, PhD, Jeffrey A. Golden, MD, Gregory Dolganov, PhD, Kirk D. Jones, MD, Samantha Donnelly, PhD, and Timothy Weaver, Bsc, all of UCSF.

The research is funded by a grant from the National Institutes of Health that is administered jointly by the Northern California Institute for Research and Education (NCIRE) and UCSF's Cardiovascular Research Institute, and is supported by the Diamond Family Foundation.

University of California - San Francisco ucsf.edu

Lking for More Information... Need Help Now! Click Here

Return Home | Return to Education Resources | Return to Informational Resources

Alpha-1 Advocacy Alliance, PO Box 202, 103 Rapidan Church Lane, Wolftown, VA 22748
Telephone: 540-948-6777 or 1-866-FOR-A1AA (1-866-367-2122) Fax # 540-948-6763
Copyright © 2006 Alpha-1 Advocacy Alliance, All Rights Reserved

Home | Disclaimer | Privacy Policy